Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 48,491 shares, a growth of 279.3% from the June 30th total of 12,783 shares. Based on an average trading volume of 388,731 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short.
Wall Street Analyst Weigh In
Several equities analysts have commented on SGIOY shares. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Finally, Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Buy”.
Read Our Latest Stock Report on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Price Performance
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%. The business had revenue of $881.71 million for the quarter, compared to analysts’ expectations of $895.52 million. As a group, research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.79 EPS for the current fiscal year.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Stories
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
